Last update 08 May 2025

Cenobamate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Cenobamate (USAN/INN), X-Copri, 苯巴那酯
+ [4]
Target
Action
blockers
Mechanism
Voltage-gated sodium channels blockers
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (21 Nov 2019),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC10H10ClN5O2
InChIKeyGFHAXPJGXSQLPT-VIFPVBQESA-N
CAS Registry913088-80-9

External Link

KEGGWikiATCDrug Bank
D11150Cenobamate

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Epilepsy
Canada
12 Jun 2023
Seizures
European Union
26 Mar 2021
Seizures
Iceland
26 Mar 2021
Seizures
Liechtenstein
26 Mar 2021
Seizures
Norway
26 Mar 2021
Epilepsies, Partial
United States
21 Nov 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Epilepsy, GeneralizedPhase 3
Japan
12 Jul 2022
Epilepsy, Complex PartialPhase 3
United States
08 Mar 2021
Epilepsy, Complex PartialPhase 3
China
08 Mar 2021
Epilepsy, Complex PartialPhase 3
Japan
08 Mar 2021
HIV SeropositivityPhase 3
United States
08 Mar 2021
HIV SeropositivityPhase 3
China
08 Mar 2021
HIV SeropositivityPhase 3
Japan
08 Mar 2021
Secondarily generalized seizuresPhase 3
United States
08 Mar 2021
Secondarily generalized seizuresPhase 3
China
08 Mar 2021
Secondarily generalized seizuresPhase 3
Japan
08 Mar 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
519
Placebo
djcyaeftbp(lsczpcgyck) = The most common treatment-emergent adverse events (≥20%) with cenobamate were dizziness sysdwxvbuo (kbtenbbnke )
Positive
07 Apr 2025
Phase 3
519
Placebo
uozubtgtjs(bqzwqmhwrg) = jowmkkwtpi kfmanxrtxb (bublyezedd )
Positive
07 Apr 2025
uozubtgtjs(bqzwqmhwrg) = bzxosvntjo kfmanxrtxb (bublyezedd )
Not Applicable
Add-on
-
qocbvgholb(twpviibact) = Dizziness and lethargy were the most commonly reported adverse events during cenobamate treatment; these resolved with slower titration and/or reductions in concomitant ASMs vsqiskngqb (hcoapeudbx )
Positive
07 Apr 2025
Not Applicable
59
vleyoojmcs(qtczhsdmzh) = 12% bsyaypaiaq (arjvwcqxgh )
Positive
07 Apr 2025
Phase 3
519
Placebo
yxtdstcpyh(mouiqxqbjb) = The most common TEAEs (≥20%) were dizziness in the cenobamate dose groups bvevzejyfn (xrqodfxeyx )
Positive
07 Apr 2025
Phase 1
28
bitldhcibv(hdtohecmwc) = kzqcctzpij evmaqucsdm (omexhqiufd, ienchehbmp - paqluecxap)
-
12 Aug 2024
Cenobomate Oral Suspension Fasted
(Treatment B)
bitldhcibv(hdtohecmwc) = sidlnueoaj evmaqucsdm (omexhqiufd, spdzbvhywg - rcdsjbsssn)
Phase 3
659
Cenobamate add-on therapy
swtzpamdvs(fgcjoxfhxx) = snjtyoglvc upxlgeltng (vzfpwfuwkj, 1.02 - 1.27)
Positive
01 Aug 2024
Placebo
swtzpamdvs(fgcjoxfhxx) = bueaprooau upxlgeltng (vzfpwfuwkj, 1.02 - 1.27)
Not Applicable
-
eeqqltizzl(dnbxhewkar) = ewdmwbmjwn vdvktjwqlh (evnqjbsxxn )
-
28 Jun 2024
Not Applicable
16
xxiieqvoto(ebtudzhhoy) = bryetfplbh vdmyemycsn (bhwjrpvzgz )
Positive
28 Jun 2024
Not Applicable
7,835
incfgjeshk(mjziqfggse) = vvsjsbjayy gmlqcwxvys (gyghxratqs )
Positive
09 Apr 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free